Floreo
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Medical Devices
Floreo is the leading virtual reality & AI therapy platform for the neurodiverse, those with conditions like autism and ADHD. Floreo's VR therapy solution is currently used by over 80 autism therapy clinics leveraging AI treatment planning and convesational therapy. And its investigational device FloreoRx is now in FDA review for De Novo clearance to treat the core aspects of autism. And through partnership with the NIH, Floreo has also developed a new ADHD intervention which has successfully completed its feasibility study and is preparing for a pivotal trial.
Company HQ City:
WASHINGTON
Company HQ State:
District Of Columbia
Company HQ Country:
United States
Year Founded:
2017
Lead Product in Development:
FloreoRx
CEO
Vijay Ravindran
Development Phase of Lead Product
NDA Preparation/In Review
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
9/2026
What is your next catalyst (value inflection) update?
FDA De Novo clearance to treat autism
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}